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Objective: The purpose of this study was to analyze the current inpatient hospital cost and Medicare reimbursement of
endovascular abdominal aortic aneurysm repair (EVAR) at different hospitals.
Methods: The cost of EVAR from October 2000 to October 2001 with two commercially available endografts (Ancure,
Guidant Endovascular Solutions, Menlo Park, Calif; and AneuRx, Medtronic AVE, Santa Rosa, Calif) was retrospectively
analyzed at seven hospitals. Three university (n  111) and four community hospitals (n  110) from different regions
of the country participated in the survey. Consecutive cases with complete financial records were included. Hospital
finance departments provided their best estimates of hospital costs, including overhead for operating room, endograft,
medical supply, bed, radiology, laboratory, and pharmacy services and reimbursement on the basis of hospital-specific
Diagnostic Related Groups (DRG) 110 or 111. Detailed hospital charges and International Clinical Diagnosis codes also
were reviewed from Universal Billing-92 forms submitted to Medicare. An additional cost analysis was performed by the
authors to validate the estimates of the hospital financial departments. Outliers of more than three standard deviations
from the mean were excluded.
Results: The mean total hospital cost was $22,999, and mean reimbursement, weighted by case mix, was $20,837,
resulting in a net loss of $2162. The majority of EVAR cost was from the device (57%) and other medical supplies (16%).
EVAR was reimbursed on the basis of DRG 110 in 78% of cases and of DRG 111 in 22%. Reimbursement varied widely
by hospital and location (mean, $20,837; range, $14,818 to $30,343; standard deviation, $5450). With the exclusion of
one hospital where reimbursement was not based on the DRG, cases reimbursed with DRG 110 resulted in an average loss
of $2200, while the average loss was $9198 with DRG 111. The mean net loss for hospitals reimbursed with the DRG
system was $3898.
Conclusion: EVAR reimbursement is presently inadequate to cover hospital expenses. Substantial financial losses occurred
at four of the participating centers. University hospitals fared surprisingly better because of higher reimbursement. (J
Vasc Surg 2003;37:272-9.)
Endovascular repair is an established method for the
treatment of infrarenal abdominal aortic aneurysms. Since
the US Food and Drug Administration approval of two
devices in September 1999, the number of endovascular
abdominal aortic aneurysm repairs (EVARs) has escalated.
An estimated 25,000 EVARs will be performed in the
United States in 2002 according to industry market re-
search provided by Guidant Endovascular Solution. Several
other devices are in development or are in clinical trials in
the United States and across the world.
Given the high expenses reported with this new tech-
nology, the cost of endovascular aneurysm repair has re-
ceived considerable attention. Thus far, most studies have
compared the cost of endovascular and open aneurysm
repair.1-11 The findings of these reports are conflicting.
Most authors report a higher total hospital cost for EVAR
in comparison2,3,7-9,11 with open repair, although
some1,4-6 have shown equal or lower costs. These compar-
isons were done on endovascular repairs performed within
clinical trials. The expanded indications in current practice,
and the increased pricing of the commercial products, make
previous analyses inapplicable in the present environment.
A complete cost analysis of new procedures such as
EVAR can be quite daunting and require evaluation from
many aspects. The cost of additional diagnostic studies,
both before and after surgery, initial equipment purchases,
and increased practice expenses, are all worthwhile issues to
consider. The economic impact of a faster recovery or, in a
few cases, earlier return to work are additional issues to
consider. The objective of this study was limited to a survey
of current hospital cost and reimbursement issues of EVAR
at different medical centers across the United States. Our
main aim was to determine whether the current reimburse-
ment for EVAR is adequate to cover hospital costs. Because
of the age group involved, Medicare is the dominant insur-
ance program covering aneurysm repair, and special atten-
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tion is given to the Diagnostic Related Groups (DRG)
reimbursement for these procedures.
Aside from initial outlay for equipment, specific cost
and reimbursement per procedure is the most significant
issue determining profitability at US hospitals from an
operational standpoint. Decisions to offer EVAR or not at
certain institutions have been linked to various perceptions
of loss or profit with this new technology, although no
studies have clearly addressed this issue after the commer-
cialization of two endograft products.
METHODS
Participating hospitals and patient cohort. Inpa-
tient hospital costs of EVAR were retrospectively reviewed
at seven hospitals. Consecutive cases with complete finan-
cial records (n  221) over a 12-month period from
October 2000 to October 2001 were included in the study.
Outliers (n  3) of more than three standard deviations
(SDs) from the mean were excluded from the primary
analysis. Forty-five other cases were excluded because com-
plete financial records were unavailable. Three university
(n  111) and four community (n  110) hospitals from
six different states provided cost data. University hospitals
included Presbyterian (n  16) and Shadyside (n  76)
Hospitals of the University of Pittsburgh Medical Center
(Pittsburgh, Pa) and Dartmouth Hitchcock Medical Cen-
ter (n  19; Lebanon, NH). Community hospitals in-
cluded Anne Arundel Medical Center (n  26; Annapolis,
Md), Meritcare Health System (n  36; Fargo, ND),
Martin Memorial Hospital (n 32; Stuart, Fla), and Mercy
Medical Center (n  16; Des Moines, Iowa). The Univer-
sity of Pittsburgh Medical Center Institutional Review
Board approved the study protocol.
Procedures were performed by vascular surgeons or
interventional radiologists with commercially available de-
vices only (Ancure, n  191; Guidant Endovascular Solu-
tions, Menlo Park, Calif; and AneuRx, n  30; Medtronic
AVE, Santa Rosa, Calif). Patient and endograft selection
for endovascular repair was based on individual physician
discretion. EVARs with nonapproved devices were ex-
cluded. Endovascular cases were captured with the Inter-
national Classification of Disease-Ninth Revision-Clinical
Modification (ICD-9) principle diagnosis code 441.4 (ab-
dominal aortic aneurysm, without rupture) or procedure
codes 39.71 (endovascular implantation of stent graft in
abdominal aorta), 38.44 (resection of abdominal aorta with
replacement), or 39.52 (other repair of aneurysm).13,14
Cases were performed after the implementation of a specific
ICD-9 procedure code for EVAR by the Center for Medi-
care and Medicaid Services (CMS) on October 1, 2000.
Hospitals costs. Hospital finance departments pro-
vided their “best estimates” (refer to Methods, Hospital
accounting methods) of total inpatient hospital costs for
each patient and a breakdown of expenses by cost center.
For the purpose of this review, eight cost centers encom-
passing all inpatient hospital expenses were defined as fol-
lows:
1. Operating room cost center included the operating
room time, anesthesia time, operating room nursing,
and recovery room costs.
2. Endograft cost was considered separately.
3. Vascular implant cost center included the expense of
additional endoluminal stents, stent grafts, and pros-
thetic grafts.
4. Medical-surgical supply cost center included equipment
used for endovascular repair, such as wires, catheters,
and balloons (except the vascular implants defined pre-
viously), and the remaining supplies used during admis-
sion.
5. Room expenses included regular floor, telemetry bed,
and intensive care room costs.
6. Pharmacy, transfusion, and laboratory services were cal-
culated together.
7. Radiology cost center included plain radiograph, ultra-
sound scan, computed tomographic scan, and other
diagnostic imaging.
8. Miscellaneous cost center included same day surgery,
physical and occupational therapy, and pulmonary care.
Because all hospital accounting methods were not iden-
tical, individual Universal Billing-92 (UB-92) forms and
detailed billing records were reviewed when feasible and
used to assign appropriate costs to the previous categories
in certain cases. The UB-92 is a standard claim form used to
submit hospital charges and report ICD-9 principle proce-
dure and primary and secondary diagnosis codes. The
UB-92 claim includes total inpatient charges and an item-
ized list of charges categorized by revenue codes. The
endograft and other implantable vascular stents were iden-
tified in Supply/Implants Revenue Code 278 and 279.
Itemized hospital bills for individual patients also were
reviewed for selected cases from each hospital when an
endograft charge was not listed on the UB-92 face sheet.
Detailed review was performed to ensure appropriate
uniform billing per institution. Several cases were identified
with no billing for the endograft or other gross errors,
usually in the endograft and implant categories. These were
corrected whenever feasible with identification of each en-
dograft and supply item used from operative records of the
individual patients and assignment of the appropriate cost
according to the hospital methodology. This detailed re-
view also allowed us to validate the finance departments
cost estimates. Financial officers from the respective insti-
tutions assisted in these corrections and approved the
methodology. These data are presented as the authors
“best estimates” of costs.
All dollar figures presented are costs in US dollars and
not charges unless specifically stated. The cost of overhead
was included in all cases and for all cost centers unless
specifically indicated. Professional fees and the cost of fol-
low-up or readmission were not included in the analysis.
Hospital accounting methods. Accounting methods
varied by hospital. Accounting was based on the ratio of
cost to charge (RCC) method at one university and two
community hospitals. The RCC accounting process has
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been described elsewhere.14 Briefly, the RCC values for the
individual cost centers (ie, radiology, laboratory, phar-
macy) are calculated by dividing the expenses incurred over
a specific time period by the total charges for that same
period. The RCC values are determined by the hospital
annually and reported to CMS. Department-specific RCCs
were calculated for each charged item to be representative
of actual costs incurred. The cost in each cost center was
determined by multiplying charges by the RCC (charge 
RCC  cost). The total cost of EVAR then was calculated
by adding the cost of the individual revenue cost centers.
The relative value unit (RVU) cost accounting system
was used at the remaining four hospitals.14,15 This account-
ing system is fully absorbable in that both direct and
indirect expenses are included. In the RVU process, ex-
penses from revenue generating centers are allocated to
each of the charge items within that department. This is
accomplished by separating expenses into categories such as
labor, supplies, equipment depreciation, and overhead. In-
dividual charge items then are assigned a weight or RVU.
The cost per category then is spread to each charge item on
the basis of its RVU. Expenses from non-revenue produc-
ing departments (overhead) are allocated to revenue-pro-
ducing departments with the Medicare Cost Report Step
Down Allocation. Charge item costs are reconciled to the
general ledger cost for each department periodically to
validate the RVU method.
Commercial software used by hospitals to track costs
included products from Enterprise Performance Systems,
Inc (St Louis, Mo) in one hospital and Meditech (Iatric
Systems, Boxford, Mass) in another. Other institutions
used proprietary accounting software to track costs.
Reimbursement. Various payors were involved in re-
imbursement for EVAR: Medicare and other payor (73%),
Medicare alone (20%), or other payor alone (7%). Because
Medicare was the major payor in 93% of cases, the Medicare
DRG 110 and 111 payments were used to calculate reim-
bursement for all cases. The DRG assigned to any proce-
dure is based on comorbidities and complications as re-
corded with ICD-9 codes. EVAR reimbursement was
based on DRG 110 or 111 as determined by the CMS for
the year 2001. DRG 110 is assigned to major cardiovascu-
lar procedures with complicating conditions. DRG 111 is
assigned to major cardiovascular procedures without com-
plicating conditions. Some examples of complicating con-
ditions that qualify for DRG 110 include emphysema, heart
failure, urinary retention, bleeding, and many others. The
base DRG payments for EVAR are higher for 110 than for
111.
DRG reimbursement is determined by several factors,
including the hospital base payment, relative weight, geo-
graphic location, and teaching or nonteaching designa-
tion.16 DRG reimbursement can be summarized by the
formula:
DRG payment ($)  (base payment  relative weight)
 DSH  IME  capital payment  outlier
with IME as indirect medical education and DSH as dispro-
portionate share hospital. The base payment is comprised
of a standardized amount that is divided into a labor and
nonlabor component on the basis of urban versus nonur-
ban classification. The labor-related component is adjusted
with a wage index that is determined on the basis of hospital
geographic location defined by Metropolitan Statistical
Area. The DRG relative weight accounts for differences in
the mix of patients treated across hospitals. The dispropor-
tionate share hospital adjustment is made to compensate
hospitals serving a relatively large volume of low-income
patients. The indirect medical education adjustment is paid
to approved teaching hospitals for the cost of medical
education on the basis of the ratio of residents to beds. The
capital payment adjustment covers capital-related expenses,
such as depreciation expense. Finally, adjustments are made
to compensate for outliers as the result of unusually expen-
sive cases. Because of differences in the previous factors,
payment for DRG 110 and 111 differed considerably be-
tween hospitals.
In this review, reimbursement by hospital was deter-
mined on the basis of the DRG-weighted reimbursement
(DRG-WR) at each center to account for differences in the
number of cases in DRG 110 and 111 at each hospital.
DRG-weighted payment was calculated with the formula:
Net profit or loss was calculated with subtracting the
mean DRG-WR from the mean total cost. Cases reim-
bursed with the DRG 110 payment were also analyzed
separately from DRG 111 to compare the net profit or loss
for EVAR by DRG class.
Reimbursement for EVAR at the Maryland hospital
was determined differently because the state has a waiver
from CMS rates.17 Reimbursement rates are set by the
Maryland Health Services Cost Review Commission
(HSCRC), and all payors must pay those rates, with the
exception that Medicare receives a 6% discount. Therefore,
Medicare pays 94% of fee-for-service charges. However,
each hospital’s charges and total revenue are constrained by
HSCRC DRG-set reimbursement limits. The Maryland
HSCRC establishes the charge per case (CPC) rate on the
basis of the DRG 110 and 111 case-mix index. If the target
CPC rate is lower than the reimbursement of 94% of
charges, then the hospital is required to reduce other
charges to meet the target revenue for all care delivered at a
particular medical center. In effect, gains realized from
DRG-WR ($) 
(DRG 110 payment  DRG 110 cases)  (DRG 111 payment  DRG 111 cases)
total number of cases
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EVAR result in reduced revenue from other hospital ser-
vices. Because the CPC rate is the effective hospital reim-
bursement, this was used as the authors’ best estimate.
Net profit or loss. Mean hospital costs and mean
DRG-WR were analyzed to determine net profit or loss.
Length of stay also was recorded. A separate analysis of cost
was done that included outliers.
RESULTS
Hospital costs and reimbursement. Mean length of
stay, total costs, DRG-WR, and net profit or loss per
hospital on the basis of the hospital’s best estimates are
shown in Table I. The mean length of stay was 2.4 days for
all patients in the study, with a range of 1.7 to 4.3 days. The
mean total cost for EVAR for all hospitals was $22,999
(range, $19,430 to $28,216; SD, $3020). Mean total costs
varied widely between hospitals. The highest average cost
of $28,216 reported by a community hospital was only
partly because of a longer length of stay. With a mean
DRG-WR of $20,837 (range, $14,818 to $34,343; SD,
$5450), the hospitals incurred a net loss of $2162 per case.
Of note, the large profit reported by one community hos-
pital is because of a specific reimbursement scheme unique
to the state of Maryland.
The authors’ best estimates of costs and reimbursement
after corrections are shown in Table II. The mean total
hospital cost for EVAR for all hospitals was $23,042. This
figure was nearly identical to the hospital’s estimate, differ-
ing by only $43. Mean total hospital costs differed slightly
at three hospitals, mainly because of errors or omissions in
charging for the endograft. The main correction intro-
duced by the authors involves the effective reimbursement
in the Maryland hospital. The figure in Table II is the CPC
value established by the Maryland HSCRC as described in
the Methods section. The mean total charge for the admis-
sion was $32,280. Because payment is set at 94% of charges,
the mean reimbursement for EVAR was $30,343, reported
in Table I. Because hospital inpatient revenue is regulated,
the CPC target rate of $18,989 is the effective hospital
reimbursement in Maryland. Factoring in of the CPC re-
sulted in a real net loss of $3098 per case, instead of an
$8256 profit.
Substantial differences existed in DRG-WR, with a
range of $14,818 to $24,915. The lowest DRG-WR of
$14,818 was the result of a higher percentage of cases
covered with DRG 111 (6/16; 37.5%) and the lower base
DRG payments at the community hospital involved. As
expected, DRG-WR was higher at the three university
hospitals compared with the community hospitals. Accord-
ing to the authors’ best estimates, the net loss across all
hospitals was higher than the hospital’s estimate at $3827.
Two university hospitals paid with the DRG system realized
a net gain for EVAR because of higher DRG payments.
Overall, EVAR resulted in a net loss according to both the
hospitals’ and the authors’ cost analyses.
Table I. Mean length of stay, total cost, DRG-weighted payment, and net profit or loss for EVAR on basis of hospitals’
best estimates
Hospital State n  221
Length of stay (d)
Mean
total cost
DRG
weighted
payment
Net profit
or loss (–)Mean Range
University affiliate PA 76 2.0 (1-16) $21,597 $19,669 –$1927
University PA 16 1.9 (1-5) $24,217 $24,915 $698
University NH 19 1.7 (1-8) $20,452 $22,277 $1825
Community FL 32 4.3 (1-12) $28,216 $16,250 –$11,966
Community ND 36 2.2 (1-9) $19,430 $17,590 –$1840
Community MD 26 2.6 (1-16) $22,087 $30,343* $8256
Community IA 16 2.5 (1-10) $24,997 $14,818 –$10,179
Mean 2.4 $22,999 $20,837 –$2162
*Reimbursement at non-Medicare rate of 94% of charges.
Table II. Mean total cost, DRG-weighted payment, and net profit or loss for EVAR on basis of authors’ best estimates
Hospital State n  221 Total cost
DRG-weighted
payment
Net profit
or loss (–)
University affiliate PA 76 $21,475 $19,669 –$1806
University PA 16 $24,385 $24,915 $530
University NH 19 $20,452 $22,277 $1825
Community FL 32 $28,216 $16,250 –$11,966
Community ND 36 $19,682 $17,590 –$2092
Community MD 26 $22,087 $18,989* –$3098
Community IA 16 $24,977 $14,818 –$10,179
Mean $23,042 $19,215 –$3827
*Reimbursement based on Maryland HSCRC CPC rate.
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Cost centers. A further breakdown of hospital ex-
penses by cost center revealed how costs were distributed
across service departments. The detailed breakdown of
hospital costs with overhead according to cost center is
shown in Table III. Most of the EVAR cost was from the
endograft, medical-surgical supplies, and operating room
services. The endovascular graft, with overhead included,
accounted for 57% of the total cost and was the single
greatest expense at each hospital. Although the cost dif-
fered between endografts, Ancure ($12,148) and AneuRx
($15,407), the additional stents or stent grafts used during
Ancure repairs resulted in similar total costs for the proce-
dure. Medical-surgical supplies, which included wires,
catheters, and other equipment, accounted for 11% of total
cost. Operating room time, anesthesia time, and recovery
room usage were bundled into one cost center and repre-
sented 12% of total expense. Other vascular implants, such
as stents, stent grafts not part of the endovascular device
(Wallgraft, Boston Scientific, Natick, Mass), and prosthetic
grafts, added a mean of $1116 (5%) to the procedure. The
remaining four cost centers contributed at total of $3703,
accounting for only 16% of the total cost when combined.
There were variations between hospitals for each cost
center. Large differences were seen in the estimated cost for
the endograft. This was because of variations in the amount
of overhead assigned to the device. Without overhead, the
mean cost for the endograft was $10,496, with less varia-
tion reported between hospitals. Additional stents were
used to different degrees during EVAR at each hospital,
resulting in a range of costs for other vascular implants. This
was the result of surgeon practice, type of endograft used
for repair, and individual patient anatomy. Smaller differ-
ences were reported for room, pharmacy, laboratory, and
other services. The cost of radiology services was similar,
except for one community hospital, where the interven-
tions were primarily performed by a radiologist, that re-
ported significantly greater expenses for the radiology cost
center.
Reimbursement for DRG 110 versus DRG 111.
Excluding the Maryland hospital, EVAR was reimbursed
based on DRG 110 in 78% of cases (n  153) and DRG
111 in 22% (n  42). As expected, significant differences
were found between hospital compensation for DRG 110
versus 111. For cases covered with DRG 110, the mean net
loss was $2200 (SD, $6554; Table IV). The mean net loss
for cases reimbursed with DRG 111 was significantly
greater at $9198 (SD, $4974; Table V). The mean net loss
for hospitals reimbursed with the DRG system was $3898.
All hospitals had a net loss in revenue for cases paid with
DRG 111, and two university hospitals profited for cases
paid with DRG 110. This was mainly the result of the
higher reimbursement at these hospitals and not the result
of lower costs. The Maryland medical center was excluded
from the previous analysis because reimbursement was not
directly related to the DRG classification.
Analysis including outliers. Cost analysis without
outliers is useful to measure the cost of the average admis-
sion. However, with an active endovascular program, com-
plex cases requiring additional supplies and longer admis-
sions because of complications are predictable. To evaluate
the global cost of EVAR, the analysis was done with inclu-
sion of outliers (n  3) greater than three SDs from the
mean. The mean length of stay increased to 2.9 days after
inclusion of these patients. With outliers, the mean total
cost increased to $24,649 and the mean DRG-WR was
$19,453. The net financial loss for all patients undergoing
EVAR increased to $5196 from $2162.
DISCUSSION
Advances in medical technology, such as novel drug
therapies and devices, are often associated with increased
costs compared with established treatment methods. To
date, this has been the case with EVAR. EVAR provides an
excellent alternative to traditional open repair in many
patients. More patients are requesting or demanding this
option as public awareness about the procedure increases.
As the clinical efficacy of EVAR continues to be studied and
debated, the cost of this technology to hospitals must be
considered. Previous reports have focused on the cost of
EVAR in comparison with open repair.1-11 Many studies
have documented a higher cost of EVAR, mainly from the
endovascular graft.2,3,7,8,11 Sternbergh and Money7 ana-
Table III. Detailed mean costs of EVAR by cost center including overhead (see text for description of individual cost
centers)
Hospital
Total
cost Endograft*
Vascular
implant†
Medical
surgical
supply
Operating
room service Room
Pharmacy
 laboratory
 blood Radiology Other
University affiliate $21,475 $13,038 $1914 $2035 $1550 $1226 $929 $308 $476
University $24,385 $12,935 $752 $1830 $5348 $664 $2413 $400 $42
University $20,452 $15,536 $1099 $1666 $1304 $1047 $542 $150 $207
Community $28,216 $15,546 $1283 $3615 $3075 $1950 $1316 $791 $640
Community $19,682 $9,361 N/A $2894 $1249 $955 $1241 $3807 $175
Community $22,087 $9,963 $2937 $2868 $3542 $1639 $719 $264 $154
Community $24,997 $15,960 $107 $2576 $2486 $1834 $696 $884 $455
Mean $23,042 $13,191 $1116 $2498 $2651 $1331 $1122 $943 $307
*Hospitals assigned varying overhead costs to endograft.
†Vascular implants are stents, stent grafts, and prosthetics other than endograft.
N/A, Not applicable.
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lyzed the cost of EVAR with one device implanted under
phase I and II clinical protocols. The authors found that
EVAR was more costly than open repair if the device cost
exceeds $5000. In addition, the 1999 mean blended Medi-
care reimbursement of $18,989 did not cover the cost of
EVAR.
In this survey, hospital reimbursement weighted by
DRG case mix resulted in an average loss of between $2162
and $3827 depending on the method of assigning reim-
bursement in Maryland. All hospitals in the study incurred
financial losses for EVAR cases paid with DRG 111. Unex-
pectedly, losses also occurred for cases with the higher
DRG 110 in four hospitals. Hospital net profit or loss for
EVAR is highly dependent on DRG reimbursement. Pay-
ment for DRG 110 is greater than DRG 111 because this
grouping includes major cardiovascular procedures with
complicating conditions. Accurate coding of comorbities
and complications is required to assure payment for all
allowable cases in DRG 110. Reimbursement for EVAR at
university medical centers and urban hospitals is generally
greater than at nonteaching, rural hospitals. Community
hospitals with low DRG 110 payments may find it difficult
to sustain EVAR programs, especially given expensive
start-up costs.
These results have important implications for EVAR. If
other hospitals have similar losses, reluctance to start new
programs or pressure to limit EVAR application may esca-
late. Hospitals with DRG weighted payments below total
costs may have significant financial losses from a high-
volume EVAR program. Losses may even be higher when
treating high-risk individuals as shown with our analysis
with the outliers.
If the number of endovascular repairs continues to
increase, focus will undoubtedly be placed on minimizing
expenses. With an already short length of stay, it will be
difficult to further reduce expenditures without a reduction
in endograft cost. This seems to be unlikely in the present
environment, given the high development cost for these
devices. As more endografts receive US Food and Drug
Administration approval, however, competition may alter
the economics of device pricing. The only other alternatives
for reducing losses would have to use different reimburse-
ment models.
Several limitations exist in our study. First, the study
may not be representative of the national practice patterns.
It is only a limited survey of costs and reimbursement at
seven US hospitals and is not universally applicable, al-
though we included university and community hospitals
from various regions of the country to make the results
more representative. Only EVAR with the two commer-
cially approved devices was considered here to sample costs
of current practice. Most repairs in the study were per-
formed with the Ancure device as compared with the more
widespread use of the AneuRx in current clinical practice.
Therefore, costs presented here may not reflect the true
actual costs for EVAR across the United States. A limited
analysis of our data does not reveal major differences in the
overall cost between devices.
Second, different accounting methods were used by the
hospitals. We solicited cost data from hospitals on the basis
of existing accounting systems because it was impossible to
apply a standard accounting methodology. RCC account-
ing is a common method for calculating hospital costs.14,15
An advantage of the RCC method is that it is the most
widely used across hospitals nationwide. The main disad-
vantage is that the RCC may not accurately calculate costs
for a specific procedure and at the individual case level. This
is especially true for procedures such as EVAR in which
Table IV. Number, mean total cost, payment, and net profit or loss for cases in DRG 110
Hospital n  153 Total cost
DRG 110
payment
Net profit
or loss (–)
University affiliate 63 $21,459 $21,310 –$149
University 12 $25,574 $27,135 $1562
University 11 $20,978 $27,460 $6482
Community 27 $28,494 $17,500 –$10,994
Community 30 $20,362 $19,016 –$1346
Community 10 $26,640 $17,886 –$8754
Mean $23,918 $21,718 –$2200
Table V. Number, mean total cost, payment, and net profit or loss for cases in DRG 111
Hospital n  42 Total cost
DRG 111
payment
Net profit
or loss (–)
University affiliate 13 $21,553 $11,719 –$9833
University 4 $20,149 $14,923 –$5226
University 8 $19,730 $15,150 –$4580
Community 5 $26,669 $9500 –$17,169
Community 6 $16,283 $10,458 –$5825
Community 6 $22,259 $9705 –$12,554
Mean $21,107 $11,947 –$9198
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medical supply costs are high. In addition, the Medicare
RCC does not cover certain nonallowable hospital expenses
and may underestimate true costs. Costs provided by hos-
pital finance departments were validated with review of UB
forms to correct gross errors. The most common findings
were failure to charge for the endograft. However, after
correcting for these errors, the authors’ best estimates of
hospital costs were similar. Clear explanation and docu-
mentation of accounting methods are necessary for future
cost analysis of EVAR. The previous issues illustrate the
inherent problems in arriving at the real hospital costs in
any study of this kind.
A third limitation is that only inpatient costs were
factored in the analysis. The cost of endovascular surveil-
lance and professional fees were not included. The costs of
readmission for complications and secondary procedures,
such as the treatment of endoleaks, were also not consid-
ered. These are not germane to the purpose of this review
because they are reimbursed separately. Whether this addi-
tional activity benefits the hospitals financially or exagger-
ates the losses cannot be gleaned from our analysis. Finally,
the initial capital required to establish an endovascular
program is substantial. Additional fluoroscopic equipment
alone ranges from $180,000 for a 12-in mobile C-arm to
$1.5 million for fixed angiosuites being installed around
the country in the operating rooms.
In addition, the effect of treatment was not measured in
terms of the cost effectiveness of EVAR as reported by Patel
et al3 in a hypothetic model. The authors concluded that
EVAR was cost effective even if the endograft cost was
$8000 to $12,000. With a mean endograft cost of more
than $13,000 with overhead and an additional $1100 from
additional vascular implants, the cost of the procedure is at
or above this threshold. A comprehensive analysis of the
cost benefit ratio of EVAR on a real patient cohort is
necessary to validate this assumption. This study was in-
tended to review the cost of EVAR only from the hospital’s
perspective and does not address the larger issues of cost
effectiveness.
CONCLUSION
EVAR was inadequately reimbursed at the hospitals
included in this study. The endograft continues to be the
single highest expense of repair. Internal analysis by
individual hospitals and larger prospective surveys of
hospital costs throughout the United States are neces-
sary to determine whether these findings are more
broadly applicable. A reappraisal of Medicare reimburse-
ment to hospitals for EVAR may be warranted.
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DISCUSSION
Dr Jeffrey W. Kronson (Whittier, Calif). We are struggling
with a lot of these same problems in our own community hospital
in California. And I was wondering if you could comment on what
seemed to be the disproportionate amount of DRG 110 payments,
almost 80% of the cases, which would imply that 80% of the stent
graft cases suffered from complications and were being paid out
that way with only 20% being uncomplicated. Could you please
comment on that?
Dr Daniel J. Bertges. Your question is why there seems to be
a high proportion of DRG 110 cases. The DRG 110 does not only
include complications as a result of the procedure. It also includes
associated comorbidities that are present before the procedure. From
our research, 70% to 80% of endovascular AAA repairs will be covered
under DRG 110. One point I wanted to bring out is that hospitals can
try to improve their bottom line through accurate coding.
Dr Clifford J. Buckley (Temple, Tex). We have looked at
this same issue in our own institution. Placing endografts in
patients that are truly poor candidates for direct surgical repair
should put their reimbursement under DRG 110, abdominal
aortic aneurysm with multiple comorbidities.
If the majority of your endograft patients are discharged in 48
hours or less, your hospital should realize a profit using the DRG
110 level of reimbursement.
Dr Bertges. In our study, the mean length of stay was 2.4
days. The number one cost of the admission was the endograft,
which accounted for nearly 60% of the total cost. Despite minimiz-
ing the time in the hospital, endovascular AAA repair resulted in a
net loss.
Dr Julie Ann Freischlag (Los Angeles, Calif). We looked at
costs at our hospital comparing endograft versus open repair of
abdominal aortic anerusysms and found, obviously, the hospital
made a lot more money if we did an open repair versus the
endograft repair. Our reimbursement was around $21,000. Did
you look at open repair in these hospitals to compare it with the
endograft repair?
And second, one of the strategies is to try to get more money
for these procedures, but that does not seem to be working very
well with healthcare corporations and Medicare. Do you have any
strategies to decrease the cost of the graft or the other supplies it
takes to put it in?
Dr Bertges. We did not, to answer your first question, look at
open repairs. This study was designed to provide a survey of cost
and reimbursement of endovascular repair.
As to ways to minimize costs, that is certainly an interesting
question. In our viewpoint, I think the initiative for any type of
push to increase the reimbursement should probably come from
hospital organizations. And as a vascular surgery community, we
can help by, number one, providing good documentation in the
medical record so your individual hospitals can get their allowable
DRG payment; but on a broader scale, we could provide some
support as to the clinical issues behind endovascular repair. But
whether we should be leading a charge to try to increase hospital
reimbursement or not, I am certainly not prepared to advocate
that. Perhaps as more devices enter the market the cost of the
endograft will decrease.
Dr William D. Turnipseed (Madison, Wis). The traditional
determinants for hospital cost are hospital length of stay and ICU
utilization with a corisk modifier of inhospital morbidity. You have
basically reduced hospital stay to the minimum by using the
endograft technology and are afflicted by the cost of the technol-
ogy, which overwhelms the advantage of reduced ICU utilization
and reduced hospital stay.
A caveat is that there are alternative less-invasive techniques
emerging that have comparable morbidity lengths of stay. In our
institution, for example, minimal incision aortic surgery has nearly
the same clinical outcome profile as an endograft; however, the
cost is much less. It cost our hospital $10,000 to put in an
endograft. The hospital makes $10,000 if we do a minimally
invasive open repair.
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